Scotiabank raised the firm’s price target on Eli Lilly (LLY) to $1,300 from $1,165 and keeps an Outperform rating on the shares. The firm is raising its price target due to Eli Lilly’s upwards earnings revision for its obesity franchise, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target raised to $1,281 from $1,182 at Truist
- Eli Lilly price target raised to $1,293 from $1,265 at BofA
- Hims & Hers confirms $49 monthly starting price for Wegovy pill copy
- Eli Lilly falls after Reuters report of $49 monthly weight loss pill
- Hims & Hers to offer copy of Wegovy pill at $49 per month, Reuters reports